VIDEO: Neurotech’s NT-501 shows promise in slowing macular telangiectasia progression
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Richard Small, CEO of Neurotech Pharmaceuticals, gives an update on NT-501, the company’s encapsulated cell therapy for macular telangiectasia.
The company recently submitted a license application to the FDA for the therapy, which delivers genetically modified therapeutic factors to the back of the eye.
“By delivering [ciliary neurotrophic factor] over a long period of time, we keep the photoreceptors healthy, and thus slow down the progression of the disease,” Small said.
He also previewed two phase 3 registration studies, which showed statistically significant results for slowing progression of the disease.
Collapse
Healio Interviews
Read more about